Augusto Filipe serves as Chief Medical Officer and General Director of Medical Affairs and Clinical Development at Tecnimede Group, where he is responsible for the strategic oversight of clinical development, medical affairs, and drug safety activities. He is also a member of the Group’s Executive Board.

With extensive experience in clinical development, regulatory science, and pharmacovigilance, Augusto holds the role of Qualified Person for Pharmacovigilance (QPPV) and is a member of the Eudravigilance Expert Working Group of the European Medicines Agency (EMA). At an international level, he actively contributes to regulatory and scientific alignment through his participation in the International Council for Harmonisation (ICH), integrating the M15 Expert Working Group on Model-Informed Drug Development (MIDD) and the Cell and Gene Therapy Discussion Group.

Augusto is a medical doctor specialised in Pulmonology and holds a degree in Medicine from the Faculty of Medicine of the University of Lisbon. He is the author of sixty peer-reviewed scientific publications across fields such as respiratory and nervous system diseases, pharmacokinetics, pharmacodynamics, drug safety, and proof-of-concept preclinical studies.